We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.52% | 3.35 | 3.30 | 3.40 | 3.35 | 3.30 | 3.30 | 164,059 | 15:18:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.28 | 3.02M |
TIDMVAL
ValiRx PLC
11 November 2021
11 November 2021
ValiRx PLC ("ValiRx" or the "Company")
Live Shareholder Q&A and Investor presentations
Live Q&A: London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, invites shareholders to join the CEO, Chairman and Corporate Development Manager in a Zoom webinar on 25 November 2021 at 2pm (UK). Registration prior to the event is recommended to ensure all notifications about the webinar are received by participants. Registration details will be available on the ValiRx website closer to the event. The format will comprise a short presentation by the Company on latest developments, followed by an invitation to shareholders to activate their cameras and speak directly with the ValiRx team. A recording of the event will be available to view from the ValiRx website shortly after the event concludes.
LSE Investor Presentation: CEO, Dr Suzy Dilly will also be presenting at this event on the evening of 7 December (6pm - 8pm (UK)). Prior registration is required directly with LSE, which can be accessed at https://us02web.zoom.us/webinar/register/1116364722800/WN_oBS-LVJrQJ-K9iQlDe3nMA. The format will be a short presentation and audience Q&A.
Corporate Update: The Company is also pleased to inform shareholders that the entry on www.clinicaltrials.gov for the recently completed VAL201 clinical trial has now been finalised with the addition of a summary of raw data results.
Dr Suzy Dilly, CEO of ValiRx commented: "I am looking forward to joining our shareholders in further live discussions as we continue building our events schedule to achieve transparent shareholder communications. Further conversations about our recent scientific and commercial advances, as well as conversations around our emerging strategy in Women's Health are important as we wish to ensure that shareholders understand how we are intending to continue to build long term value into the Company."
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 Dr Suzanne Dilly, CEO 796496 www.valirx.com Suzanne.Dilly@valirx.com Cenkos Securities Limited (Broker) Tel: +44 (0) 20 7397 Russell Kerr/Michael Johnson (Sales) 8900 Callum Davidson/Giles Balleny (Corporate Finance) --------------------------
Notes for Editors
About ValiRx
ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary
companies for further clinical development and commercialisation. https://www.valirx.com/
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRADZMMMGGDGMZZ
(END) Dow Jones Newswires
November 11, 2021 02:00 ET (07:00 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions